DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.

The Company's data was presented in a poster entitled, "Update on Phase I/II study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma."

DelMar is conducting a multicenter Phase I/II clinical study with VAL-083 in patients with recurrent GBM. Eligible GBM patients must have failed both Avastin® (bevacizumab) and Temodar® (temozolomide) unless either of these therapies was contraindicated. ( Identifier NCT01478178). Data from the Phase I dose-escalation portion of the study was presented at ASCO. Dose limiting toxicity was observed at a dose of 50mg/m2/day; no drug-related severe adverse events were reported and myelosuppression was mild at doses ≤40mg/m2/day. Preliminary analysis suggested a dose-dependent and clinically meaningful survival benefit in GBM patients whose tumors had progressed following standard treatment with temozolomide, radiotherapy, bevacizumab and a range of salvage therapies.

"We view the trend toward a meaningful survival benefit, and at doses that were well tolerated by patients, as highly promising for the potential of VAL-083 to offer a new treatment alternative for GBM patients. Our subsequent and more detailed analysis of data from the Phase I portion of this trial continues to support these observations," stated Jeffrey Bacha, DelMar's president and CEO.

The sub-group analysis for patients receiving up to 5 mg/m2 daily x 3 every 21 days (low dose) versus those patients receiving 30mg/m2 or 40mg/m2 (high dose) was presented today at the GBM2015 meeting. In summary, the data indicated:

  • Patients in the low dose sub-group had a median survival of 5 months versus median survival of 9 months for patients in the high dose sub-group following initiation of VAL-083 treatment (p = 0.04).
  • Increased survival was observed at 6, 9 and 12 months following initiation of treatment in the high-dose sub-group compared to the low dose sub-group.
  • Survival was not correlated with screening Karnofsky performance status (R2KPS = 0.03) or subject age at screening (R2AGE = 0.01).
  • Survival was not correlated with the localization of either the initial or recurrent lesion.
  • A longer time to progression following front-line temozolomide or second line bevacizumab treatment was not correlated with a survival benefit following initiation of VAL-083 therapy.
  • All patients had failed standard treatments and one or more salvage therapies prior to initiation of VAL-083 (median number of prior therapies = 3 for both the low and high dose sub-groups). No commonalities in prior therapy were observed to correlate with survival.
  • Survival was not correlated with MGMT expression in either the low dose or high dose sub-group.

"These analyses show a diminished possibility that factors, other than the proposed clinical activity of VAL-083, are responsible for the observed dose-dependent survival benefit following treatment," stated Mr. Bacha.

The Company has initiated a Phase II expansion cohort for the refractory GBM study at a dose of 40mg/m2 with approximately 14 patients expected to be enrolled. The purpose of the Phase II expansion cohort is to gain additional information about the safety and efficacy of VAL-083 at the 40mg/m2 dose prior to advancement into registration-directed Phase II/III clinical trials.

  • To date, 20 patients have been screened and eight (8) patients have initiated treatment with VAL-083 at the 40mg/m2 dose.
  • To further explore the therapeutic window of VAL-083, three (3) patients have also initiated treatment at an interim dose of 45mg/m2.
  • The Phase II expansion cohort may be continued at the higher 45mg/m2 dose if safety data warrants.

Further information on the trial design can be found on the company's website at

"We are pleased with the momentum of our enrollment in the trial. We look forward to presenting further data from the Phase II expansion study as we continue activities geared toward the initiation of a registration-directed Phase II/III clinical trial over the course of the next several months," added Mr. Bacha.


DelMar Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Components of the gut microbiome could be used to better predict efficacy of CAR-T cell therapy